MAP Share Price Performance
AU$0
-0.10 (-100.00%)
Price AU$0
Fair ValueAU$0.12
Share Pricen/a
Narrative Update • Aug 07
Microba Life Sciences Limited Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 7 Fair Values set on narratives written by author
MAP Community Narratives
AN
Fair Value
·Fair Value AU$0.12 51.8% undervalued intrinsic discount
Microbiome Diagnostics And Therapeutics Will Reshape Chronic Disease Management Over The Long Term
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value
·Fair Value AU$0.12 52.5% undervalued intrinsic discount
Gut Microbiome Diagnostics Will Drive Powerful Long-Term Upside Potential
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value
·Fair Value AU$0.14 59.3% undervalued intrinsic discount
Microbiome Testing Reliance Will Pressure Margins Yet Partnering Optionality May Still Emerge
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Microbiome Diagnostics And Therapeutics Will Reshape Chronic Disease Management Over The Long Term
Microba Life Sciences wants to turn gut microbiome testing into a more routine part of how doctors manage long-running digestive and chronic health problems. The upside depends on doctors adopting its newer tests fast enough to replace older products and on partner deals for microbiome treatments arriving before cash pressure forces tough choices.Read more
AN
AU$0.12
51.8% undervalued intrinsic discount
Fair Value
Profit Margin
4.95%
Future PE
65.1x
Price in 2029
AU$0.11
Gut Microbiome Diagnostics Will Drive Powerful Long-Term Upside Potential
Microba Life Sciences aims to turn growing medical interest in the gut microbiome into widely used tests and related products, with the chance to scale quickly through data tools and big diagnostic partners. The upside depends on doctors adopting these tests fast enough—and on new deals around its therapy pipeline—before cash runs tight.Read more
AN
AU$0.12
52.5% undervalued intrinsic discount
Fair Value
Profit Margin
4.99%
Future PE
57.4x
Price in 2029
AU$0.11
Microbiome Testing Reliance Will Pressure Margins Yet Partnering Optionality May Still Emerge
Catalysts About Microba Life Sciences Microba Life Sciences provides microbiome based diagnostic testing and develops live biotherapeutic assets aimed at chronic disease. What are the underlying business or industry changes driving this perspective?Read more
AN
AU$0.14
59.3% undervalued intrinsic discount
Fair Value
Profit Margin
4.81%
Future PE
63.51x
Price in 2029
AU$0.21
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
MAP: Recent Equity Raising Will Support Future Upside Potential
Fair Value: AU$0.12 51.8% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
MAP: Upcoming Capital Raise Will Support Future Microbiome Commercialisation Plans
Fair Value: AU$0.12 52.5% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Microbiome Testing Reliance Will Pressure Margins Yet Partnering Optionality May Still Emerge
Fair Value: AU$0.14 59.3% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Microba Life Sciences Limited Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
- -0.028
- 46.77%
- -132.53%
- 2.5%
About MAP
- Founded
- 2017
- Employees
- n/a
- CEO
- WebsiteView website
Microba Life Sciences Limited provides microbiome testing, supplements, and analysis services in Australia, Europe, New Zealand, the United Arab Emirates, the United Kingdom, the United States, Asia, and Ireland. It operates in two segments, Testing Services and Supplements, and Research and Development. The company also develops pathology, therapeutics, and diagnostics services based on the human gut microbiome. In addition, it offers MetaPanel, a metagenomic test for pathogen detection; MetaXplore that provides a range of diagnostics solution under the Co-Biome brand; research testing services; and data-driven therapeutics platform that develops therapies for ulcerative colitis, and inflammatory bowel and autoimmune diseases, as well as microbiome databank. Microba Life Sciences Limited was incorporated in 2017 and is based in Brisbane, Australia.
